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Abstract
Background: Sirtuins (Sirt), a family of nicotinamide adenine nucleotide (NAD) dependent deacetylases, are implicated in
energy metabolism and life span. Among the known Sirt isoforms (Sirt1-7), Sirt3 was identified as a stress responsive
deacetylase recently shown to play a role in protecting cells under stress conditions. Here, we demonstrated the presence of
Sirt3 in neurons, and characterized the role of Sirt3 in neuron survival under NMDA-induced excitotoxicity.
Methodology/Principal Findings: To induce excitotoxic injury, we exposed primary cultured mouse cortical neurons to
NMDA (30 mM). NMDA induced a rapid decrease of cytoplasmic NAD (but not mitochondrial NAD) in neurons through poly
(ADP-ribose) polymerase-1 (PARP-1) activation. Mitochondrial Sirt3 was increased following PARP-1 mediated NAD
depletion, which was reversed by either inhibition of PARP-1 or exogenous NAD. We found that massive reactive oxygen
species (ROS) produced under this NAD depleted condition mediated the increase in mitochondrial Sirt3. By transfecting
primary neurons with a Sirt3 overexpressing plasmid or Sirt3 siRNA, we showed that Sirt3 is required for neuroprotection
against excitotoxicity.
Conclusions: This study demonstrated for the first time that mitochondrial Sirt3 acts as a prosurvival factor playing an
essential role to protect neurons under excitotoxic injury.
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Introduction
Continuous supply of energy is crucial for neuron survival due
to the requirement for large amounts of energy for high metabolic
processes coupled with an inability to store energy [1,2].
Therefore, neurons are highly susceptible to insults that lead to
energy depletion, such as oxidative stress, excitotoxicity, and DNA
damage [3,4]. As a critical factor in energy metabolism for cell
survival, nicotinamide adenine dinucleotide (NAD) has drawn
considerable interest. NAD is an essential molecule playing a
pivotal role in energy metabolism, cellular redox reaction, and
mitochondrial function. Recent studies have revealed that
maintaining intracellular NAD is important in promoting cell
survival in various types of diseases, including axonal degenera-
tion, multiple sclerosis (MS), cerebral ischemia, and cardiac
hypertrophy [5,6,7,8,9,10,11,12]. Loss of NAD decreases the
ability of NAD dependent cell survival factors to carry out energy
dependent processes, leading to cell death.
PARP-1, a major NAD metabolizing enzyme, hydrolyzes NAD
to nicotinamide and produces poly (ADP) ribose polymers (PAR)
upon activation under pathological condition, and leads to severe
impairment of energy metabolism with almost complete depletion
of cytosolic and nuclear NAD [13,14,15,16]. Genotoxic injury,
overstimulation of N-methyl-D-aspartate (NMDA) receptors, or
oxidative stress has been reported to activate PARP-1 in neurons
[17,18]. PARP-1 mediated NAD depletion results in mitochon-
drial permeability transition (MPT) causing cell death under DNA
damaging injury [19,20]. Our recent study showed that NAD
depletion is a causal event in PARP-1-mediated cell death in
astrocytes [19], neurons [21], and cardiac myocytes [22].
The silent information regulator 2 (SIR2) is a family of proteins
with NAD-dependent deacetylase activity highly conserved from
bacteria to humans [23], and is required for gene silencing and life
span extension [24,25,26,27]. Seven isoforms of the mammalSir2
homolog, sirtuin (Sirt) 1–7, are known to be expressed in mammals
[28]. As broader ranges of substrates were found, many cellular
functions of Sirts have been revealed, including senescence,
apoptosis, energy metabolism, and stress resistance [29,30,
31,32,33]. Sirt1 serves as a founding member of this family, and
evidence of its role in neuronal death has recently been reported.
Overexpression of Sirt1 and the use of the Sirt1 agonist,
resveratrol, were neuroprotective against amyloid beta toxicity
by reducing microglial NF-kappaB signaling [34]. Sirt1 was shown
to protect neurons against neurodegeneration in Alzheimer’s
disease and amyotrophic lateral sclerosis [35]. Sirt3 was the only
sirtuin implicated in extension of life span in human [36], and
recent evidence have shown its involvement in mitochondrial
energy metabolism and biogenesis [37] and preservation of ATP
biosynthetic capacity in the heart [38]. Sirt3 was shown to regulate
the activity of acetyl-CoA synthetase 2 (AceCS2), an important
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tricarboxylic acid (TCA) cycle. In these studies, Sirt3 knockout
resulted in a marked decrease of basal ATP level in vivo [39].
Recent studies in cardiomyocytes demonstrated the protective role
of Sirt3 from oxidative stress and hypertrophy [11,40]. Accord-
ingly, these evidences suggest that Sirt3 could also have a pivotal
role in protecting neurons from injury due to conditions that
promote bioenergetic failure, such as excitotoxicity.
In this study, we demonstrated the presence of Sirt3 in neurons,
and explored the role of Sirt3 in protecting neurons against
excitotoxic injury. We found that Sirt3 expression was increased in
mitochondria following PARP-1 mediated NAD depletion under
excitotoxic injury. By modulating Sirt3 levels in neurons using
either overexpression or knockdown, we provided evidence to
show that Sirt3 contributes to neuronal protection by suppressing
oxidative stress. This study provides the first evidence that Sirt3
plays an important role in neuronal survival against an excitotoxic
insult.
Results
NAD depletion causes neuronal death with excitotoxic
injury
Excitoxicity induces energy failure by increased consumption of
ATP, during which process NAD, an important factor in energy
metabolism, rapidly drops [9,17]. First, we examined the effect of
NMDA receptor activation on NAD levels upon prolonged
exposure to NMDA that leads to ,50% death [41,42]. NAD
was measured in both total cell fraction and mitochondria fraction
of primary neuron cultures treated with 30 mM NMDA.
Consistent with our previous study showing the selective depletion
of cytosolic NAD following PARP-1 activation under genotoxic
stress [20,21], we observed a selective NAD depletion in the
cytosol but not in mitochondria of neurons at the indicated time
points after NMDA treatment (Fig. 1A). No cell death was found
4 h after NMDA exposure (data not shown). Prolonged exposure
to NMDA induced nearly 50% neuronal death after 24 hours. To
examine whether NAD depletion contributed to NMDA-induced
neuronal death, we treated neurons with NMDA alone or NMDA
with exogenous NAD, which we have previously shown to increase
cellular NAD [21]. If loss of cellular NAD causes neuronal death,
then treatment with exogenous NAD should be able to rescue
neurons from prolonged exposure to NMDA. Treatment with
exogenous NAD dose dependently rescued neurons by restoring
cellular NAD levels (Fig. 1B and 1C), suggesting that loss of
cellular NAD levels is the cause of neuronal death. NAD treatment
with NMDA led to a slightly higher NAD level than NAD alone,
though not statistically different from NAD alone. These data
showed that cellular NAD level plays an important role as a critical
factor in determining cell survival under excitotoxic injury.
PARP-1 activation is involved in NAD depletion in NMDA-
treated neurons
Mounting evidence has indicated that PARP-1 is excessively
activated in neurons by NMDA mediated excitotoxicity or brain
ischemic injury leading to cell death by NAD depletion [13,16,17].
In order to verify that PARP-1 is involved in NMDA-induced
NAD depletion, we examined whether PARP-1 is activated in
neurons after NMDA treatment. PAR formation was significantly
increased as early as 15 min after NMDA treatment, with a peak
in signal 1 hr followed by a sharp decrease (Fig. 2A). Inhibition of
PARP-1 with PJ 34 or DPQ significantly attenuated NAD
depletion in NMDA-treated neurons (Fig. 2B). The decrease of
total NAD with excitotoxic insult is consistent with our previous
studies showing a decrease in total NAD with PARP-1 activation
[20], and suggests that the decrease is due to depletion of cytosolic
NAD and not mitochondrial NAD. In neuron cultures lacking
PARP-1, neuronal death and NAD depletion with excitotoxic
injury were significantly reduced (Fig. 2C and D), and confirms
that activated PARP-1 consumes enormous amount of NAD
inducing neuronal death. The lack of complete protection in
PARP-1-deficient cells is in accord with previous reports [21,43].
Mitochondrial Sirt3 is increased following PARP-1-
mediated NAD depletion
Next, we explored the downstream event following NAD
depletion in neurons exposed to excitotoxic injury. Recently, Sirt3
as well as Sirt1 has been shown to control cellular responses to
stress due to its NAD -dependent deacetylase function [44,45,46].
Therefore, we tested whether Sirt1 or Sirt3 serve as an important
mediator for neuronal survival under excitotoxicity. We detected
changes in the level of the short form (28 kD) of Sirt3 [46]. The
Sirt3 antibody was verified in tissue from wt and Sirt3 knockout
mice (Figure S1). The antibody recognized both the short (28 kD)
Figure 1. NAD depletion underlies excitotoxic neuronal death.
(A) NAD level was measured in total cellular and mitochondrial fractions
in mouse primary cortical neuron cultures exposed to NMDA 30 mM for
indicated times. (mean 6 SEM; n=8; *P,0.01, difference from
untreated control). (B) Cell death was assessed by measurement of
LDH release (mean 6 SEM; n=8 ; *P,0.01, difference from NMDA
alone). (C) NAD level was measured in neurons 4 h after exposure to
NMDA 30 mM alone, NMDA plus various doses of NAD, or NAD alone
(mean 6 SEM; n=4; *P,0.01, difference from untreated control;
**P,0.01, difference from NMDA alone).
doi:10.1371/journal.pone.0014731.g001
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present in the tissue obtained from Sirt3 KO animals. Sirt3 protein
level (28 kD) was markedly increased in neurons 1 hr following
excitotoxic injury, whereas we found no significant change in Sirt1
protein levels with NMDA receptor activation (Fig. 3A). Since
neuronal death and NAD depletion were significantly inhibited by
PARP-1 inhibition, we examined the effect of inhibiting PARP-1
on the increase of Sirt3 protein levels. NMDA-induced increase of
Sirt3 was attenuated by DPQ (Fig. 3B). Therefore, our data
demonstrated that the increase in neuronal Sirt3 with excitotoxic
injury is dependent on PARP-1 activation.
In addition to Sirt3, two other sirtuin isoforms (Sirt4 and Sirt5)
were reported to localize in mitochondria. We next tested if these
sirtuin isoforms were also increased with excitotoxic conditions.
We examined the expressions of these mitochondrial sirtuins in
neurons of WT and PARP-1 knock out (KO) mice. We found a
time-dependent increase in Sirt3 levels with NMDA receptor
activation in WT neurons, whereas the expression of Sirt4 or Sirt5
was not changed (Fig. 3Ci). Furthermore, the increase in Sirt3
protein level was not found in neurons cultured from PARP-1
2/2
mice (Fig. 3Cii). These data further demonstrated that the increase
in Sirt3 proteins are dependent on PARP-1 activation.
To determine if NMDA induces an increase in the Sirt3 long
form in addition to the short form of Sirt3, we examined the
protein level of both forms of Sirt3 in NMDA treated neurons.
The Sirt3 long form (44 kD) was not significantly changed by
NMDA while the short form of Sirt3 (28 kD) was significantly
increased (Fig. 4Ai). The increase in Sirt3 was further confirmed in
mitochondrial fraction of neurons, which was detected within
15 min after exposure to NMDA (Fig. 4Aii). Sirt3 mRNA
expression was increased in neurons by about 20% within
15 min after exposure to NMDA, which was maintained
throughout the rest of the time points after NMDA exposure
(Fig. 4Bi and ii). Immunostaining for Sirt3 in neurons showed that
Sirt3 was localized preferentially in the nucleus under basal
condition, whereas it was detected in both the mitochondria as
well as the nucleus after NMDA treatment (Fig. 4C). Collectively,
these results demonstrated that NMDA receptor activation
increased mitochondrial Sirt3 in neurons through PARP-1-
mediated NAD depletion.
Increase in neuronal Sirt3 expression and deacetylase
activity is prevented by NAD treatment
Having demonstrated that PARP-1 activation is upstream of the
increase in mitochondrial Sirt3 (Fig. 4), and having previously
shown that NAD depletion was necessary and sufficient for PARP-
1-mediated mitochondrial failure [21], we next tested whether the
decrease in NAD was sufficient to promote Sirt3 processing. NAD
glycohydrolase (NADase), an NAD catabolizing enzyme, was
introduced into cultured neurons using a bioporter protein
transfection method [47], a technique we have recently shown
not only to decrease cytosolic NAD without PARP-1 activation
(and therefore the lack of PAR formation), but also to selectively
decrease cytosolic NAD and not mitochondrial NAD [21].
Introduction of NADase reduced neuronal NAD levels by about
50% relative to control and bioporter alone (vehicle control) within
4 hrs (Fig. 5A), consistent with our previous report [21]. NADase
treatment of cultured neurons without bioporter transfection
reagents did not decrease NAD levels (data not shown), indicating
that NADase effects are not extracellular [21]. Therefore, we
utilized this method to decrease cytosolic NAD independent of
PARP-1 activation in order to determine if a decrease in NAD
promoted an increase in Sirt3 level. NADase treatment with
bioporter protein transfection increased Sirt3 protein level by 68%
(Fig. 5B), indicating that NAD depletion mediated the increase in
Sirt3, and suggesting that the NMDA-induced increase in Sirt3
expression is mediated by NAD depletion.
Figure 2. PARP-1 activation depletes cellular NAD in NMDA-treated neurons. (A) Western blot of PAR in neurons exposed to NMDA
(30 mM) for indicated times. The signal of PAR peaked 1 hr after NMDA treatment. b-actin was used as a loading control. (B) NAD level was measured
in neurons 4 h after exposure to NMDA alone, NMDA plus PJ34 (100 nM), or NMDA plus DPQ (25 mM) (mean 6 SEM; n=4; *P,0.01, difference from
untreated control; **P,0.01, difference from NMDA alone). (C) LDH was measured in neuron cultures of WT or PARP-1 KO mice 24 h after NMDA
exposure. (mean 6 SEM; n=8;*P,0.01, difference from the relevant controls of PARP-1 KO culture). (D) NAD level was measured in WT or PARP-1 KO
cultures exposed to NMDA 30 mM for indicated times (mean 6 SEM; n=8;*P,0.01, difference from the relevant controls of PARP-1 KO culture).
doi:10.1371/journal.pone.0014731.g002
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marker for deacetylase activity. NMDA treatment induced the
decrease in some deacetylase substrates with acetyl-lysine,
indicating an increase in deacetylase activity in NMDA-treated
neurons (Fig. 5C). The decrease in acetylation corresponded with
the increase in Sirt3 protein level (Fig. 4Ai and 5C), suggesting the
involvement of Sirt3 in this increased deacetylation in NMDA-
treated neurons. Because Sirt3 was increased in response to the
depletion of cytosolic NAD following excitotoxic injury, we next
examined whether NAD replenishment affect the expression of
Sirt3 in neurons (Fig. 5D). The increase of Sirt3 along with its
deacetylase activity in NMDA-treated neurons was reversed with
exogenous NAD treatment in a dose-dependent manner (Fig. 5D).
We demonstrated that exogenous NAD treatment protected
against NMDA treatment (Fig. 1B). Here, we showed that
exogenous NAD treatment increased PAR formation from
NMDA treatment alone (Fig. 5D), indicating that NAD treatment
promoted PARP-1 activation and suggesting that protection by
NAD treatment is not due to PARP-1 inhibition. In accordance
with our recent report [21], these results demonstrated that NAD
depletion, and not an increase in free PAR formation, is a major
cause of PARP-1-mediated neuronal death in excitotoxic injury.
A previous study demonstrated that Sirt3 is the primary
mitochondrial deacetylase [48]. We confirmed the effect of NAD
on Sirt3 activity by measuring acetyl lysine in mitochondrial
fractions isolated from NMDA treated neurons. The level of acetyl
lysine was decreased in mitochondrial fractions of neurons upon
NMDA exposure, which was restored by exogenous addition of
NAD (Fig. 5E). In neurons exposed to NAD alone without
NMDA, the signal of acetyl lysine was not changed (Fig. 5C and
5E), suggesting no effect of NAD on Sirt3 activity under normal
condition. These data indicated that NAD depletion leads to an
increased expression and activity of mitochondrial Sirt3 in
neurons, suggesting that Sirt3 may play a role as a critical factor
in determining neuronal survival by translocating to mitochondria
and affecting its function.
Oxidative stress by NAD depletion increased
mitochondrial Sirt3 expression
Oxidative stress has been shown to be a critical downstream
event leading to neuronal death after NMDA receptor activation
[49,50,51,52,53]. However, there is a lack of direct evidence in the
literature demonstrating ROS-mediated PARP-1 activation with
NMDA treatment. Because we demonstrated that PARP-1-
mediated NAD depletion occurs in our model, we examined
whether NMDA induces ROS production and therefore PARP-1
activation and NAD depletion in our excitotoxic injury model.
Increased reactive oxygen species (ROS) production in neurons
was evaluated by oxidation of dihydroethidium (HEt) by
superoxide into the fluorescent ethidium moiety. An increase in
ROS production was detected in neurons 4 h after 30 mM NMDA
treatment, which was blocked by exogenously added NAD
(Fig. 6A). This indicated that NAD depletion directly mediated
the increase in ROS production in NMDA-treated neurons, and
suggested that NAD depletion is upstream of a source of ROS
production.
In order to further clarify the temporal correlation of ROS
production and NAD depletion, we examined whether NAD
depletion by NMDA treatement is prevented by antioxidants. We
used a vitamine E analogue (Trolox) or a neuronal NOS inhibitor
(7-nitroindazole, or 7-NI). Neither Trolox nor 7-NI prevented
NAD depletion in NMDA-treated neurons, further suggesting that
NAD depletion is an upstream event of NMDA-induced oxidative
stress (Fig. 6B). Because NAD depletion induces oxidative stress,
we explored the possibility that oxidative stress could be involved
in the increased Sirt3. The increased expression of Sirt3 in
NMDA-treated neurons was reduced by treatment with either
trolox or 7-NI, which demonstrated that oxidative stress by NAD
Figure 3. Mitochondrial Sirt3 is markedly increased in NMDA-treated neurons following PARP-1 activation. (A) Western blots of Sirt1
and Sirt3 in neurons exposed to NMDA (30 mM) for indicated times. (B) Western blot of Sirt3 in neurons 4 h after exposure to NMDA (30 mM) with or
without DPQ (25 mM). (C) i. Western blots of mitochondrial sirtuins, Sirt3, Sirt4, and Sirt5 in WT and PARP-1 KO neurons exposed to NMDA 30 mM for
indicated times. ii. The expression level of Sirt3 in WT and PARP-1 KO neurons was normalized with actin and quantified to the relevant control value
(t=0). Similar results were observed from three independent experiments (mean 6 SEM; n=3; *P,0.01, difference from control).
doi:10.1371/journal.pone.0014731.g003
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(Fig. 6C). In order to further test whether the increase in
ROS production induces Sirt3 expression, we treated neurons
with a peroxynitrite generator, 3-morpholinosydnonimine (SIN-1)
(Fig. 6D). Sirt3 protein levels were increased time dependently
after SIN-1 treatment, which provides a clear evidence for the
involvement of oxidative stress in increased Sirt3 expression in
neurons.
Sirt3 acts as a prosurvival factor in neurons under
excitotoxic injury
Recently, the protective effect of Sirt3 under oxidative stress was
shown in cardiomyocytes [40], where it was shown that Sirt3
reduced ROS generation in cardiomyocyte under cardiac
hypertrophy by enhancing antioxidant enzymes such as manga-
nese superoxide dismutase (MnSOD) and catalase. Indeed, our
evidence is in support of these findings (Fig. 6). To examine
whether Sirt3 plays a protective role in neurons, we observed
mitochondrial ROS generation in neurons transfected with
pIRES2 ZsGreen-1 with or without Sirt3 at 24 hrs after NMDA
treatment. In neurons overexpressing Sirt3, mitochondrial ROS
generation was significantly inhibited compared with in neurons
expressing control vector only, implicating the protective role of
Sirt3 in neurons (Fig. 7A). To further explore the protective role of
Sirt3 in neurons under excitotoxic injury, we examined neuronal
viability by staining neurons with Hoechst and counting the
number of pyknotic neuron bodies in cultures overexpressing Sirt3
or control vector 24 hrs after NMDA treatment. Neuronal death
was significantly reduced in cultures transfected with Sirt3,
suggesting a critical role of Sirt3 in neuronal survival under stress
condition (Fig. 7B). To confirm the prosurvival effect of Sirt3, we
knocked down Sirt3 in neurons using Sirt3 siRNA. Knockdown of
Sirt3 exacerbated excitotoxic neuronal death, whereas neurons
transfected with negative control siRNA showed no difference in
Figure 4. The expression and translocation of mitochondrial Sirt3 is increased in neurons after NMDA treatment. (A) i, Western blot of
the long (L) and short (S) forms of Sirt3 in neurons treated with NMDA 30 mM at indicated times. ii,Western blot of Sirt3 in mitochondrial fraction (M)
of neurons exposed to NMDA 30 mM for indicated times. Cox IV was used as a loading control. (B) i, RT PCR analysis of Sirt3 in neurons exposed to
NMDA 30 mM for indicated times. ii, The mRNA level was normalized to the control (ctrl). Similar results were observed in three independent
experiments (mean 6 SEM; n=3; *P,0.01, difference from control). (C) Confocal analysis of Sirt3 localization (green) in neurons with or without
NMDA 30 mM for 4 hrs. Nucleus and mitochondria were detected with DAPI and MitoTracker red, respectively.
doi:10.1371/journal.pone.0014731.g004
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transfection (Fig. 7C). These results showed the robust evidence
of the pro-survival role of Sirt3 in neurons under excitotoxic stress.
Discussion
Mitochondrial localization of Sirt3 plays a role in various
mitochondrial functions, such as maintaining basal ATP level and
regulating apoptosis. Sirt3 has been shown to regulate energy
homeostasis [38]. Recent studies have suggested the protective role
of Sirt3 in cells under stress condition. In this study, we i) identified
the presence of Sirt3 in neurons, and ii) demonstrated that Sirt3
plays a role as a prosurvival factor in neurons against excitotoxic
injury. We found that under excitotoxic injury, intracellular
depletion of NAD with induced increased expression of Sirt3 in
mitochondria. NAD depletion was induced either by PARP-1
activation, or by protein transfection of NADase, both of which
have been shown by our group to selectively decrease cytosolic
NAD [19,20,21]. ROS produced following PARP-1 mediated
NAD depletion was involved in the increased expression of Sirt3.
Overexpression of Sirt3 reduced NMDA-induced ROS genera-
tion, thereby preventing neuronal death, whereas knockdown of
Sirt3 enhanced neuronal death. This study is the first evidence
demonstrating that the increase in mitochondrial Sirt3 contributes
to neuroprotection from excitotoxicity.
Excessive activation of PARP-1 induces neuronal death under
stress conditions such as DNA damage, excitotoxicity, or oxidative
stress [17,54]. PAR has been shown to induce mitochondrial
release of AIF and cell death [15,55]. However, our previous
studies have shown that NAD depletion is the cause of PARP-1-
mediated cell death and exogenous addition of NAD effectively
inhibited cell death [19,21,56]. Moreover, we have shown that
activated PARP-1 depleted most of the cytosolic NAD and then
consumed the mitochondrial NAD only after MPT permits
mitochondrial NAD to exit into the cytosol [19,20]. In accordance
with our previous findings, this study demonstrated that PARP-1-
mediated NAD depletion is responsible for neuronal death with
chronic exposure to low-dose excitotoxic agents [21,57]. Addition
Figure 5. Intracellular NAD depletion causes the increased expression and activation of mitochondrial Sirt3. (A) NAD levels were
measured in neurons transfected with NADase using Bioporter. NADase transfection produced a decrease in neuronal NAD content, as measured
4 hours after Bioporter tansfection (mean 6 SEM; n=4; *P,0.01, difference from control). This decrease was not observed in cultures treated with the
Bioporter vehicle alone. (B) Western blot of Sirt3 in neurons with or without NADase at 4 hr after transfection.. The expression level of Sirt3 was
normalized with actin and quantified to the control value (mean6 SEM; n=3; *P,0.01, difference from control). (C) Western blot of acetyl lysine in
neurons exposed to NMDA 30 mM for indicated times or NAD alone. (D) The expression of Sirt3, acetyl lysine, and PAR in neurons at 4 hr after the
exogenous addition of various concentrations of NAD. (E) Western blot of acetyl lysine in mitochondrial fraction (M) of neurons exposed to NMDA
30 mM, NMDA 30 mM with exogenous NAD, or NAD alone for 4 hrs.
doi:10.1371/journal.pone.0014731.g005
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effective [11,19,21]. We demonstrated that NAD uptake into cells
is mediated by P2X7 receptor-gated channels [21]. Activation of
P2X7 receptors occurs under basal conditions, and P2X7
receptors are further activated in injury conditions and allows
for an increase in permeability. Therefore, it is not surprising that
NAD levels are further increased under excitotoxic conditions. In
addition, we have unpublished data suggesting that NAD uptake
into cells is increased when cells are exposed to oxidative injury. In
this study, intracellular NAD level was higher in neurons treated
with NAD in the presence of NMDA than those treated with NAD
alone (Fig. 1C).
In the present study, we demonstrated that cytosolic NAD
decreased rapidly in neurons within 4 hr after NMDA treatment,
yet mitochondrial NAD levels remained unchanged. This is
consistent with previous findings that PARP-1 activation selec-
Figure 6. Oxidative stress by NAD depletion increased mitochondrial Sirt3 expression. (A) Fluorescence image of the oxidized
dihydroethidium (HEt) in neurons 4 h after exposure to control (media exchange), NMDA (30 mM) alone, or NMDA plus NAD (5 mM). (B) Cellular NAD
level was measured in neurons 4 h after exposure to control, NMDA alone, NMDA plus trolox (100 mM), or NMDA plus or 7-NI 100 nM for 4 hrs (mean
6 SEM; n=8; *P,0.01, difference from untreated control). (C) Western blot of Sirt3 in neurons treated similarly as (B). The expression of Sirt3 was
normalized to actin and quantified to the control value (mean6 SEM; n=3; *P,0.01, difference from control). (D) Western blot of Sirt3 in neurons
treated with SIN-1 1 mM for indicated times.
doi:10.1371/journal.pone.0014731.g006
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and utilization for PAR formation [20,21]. In support of this, it
was found that Sirt3 functioned as a mitochondrial NAD -
dependent deacetylase [58], and the results from our findings
imply that the NAD -dependent deacetylase activity of Sirt3 in
mitochondria is maintained due to the preservation of mitochon-
drial NAD, whereas Sirt1 deacetylase activity is impaired due to
depletion of cytosolic NAD. Consistent with our study, it was
shown that maintenance of mitochondrial NAD under stress
condition can promote cell viability even though cytosolic and
nuclear NAD is depleted [59]. Our studies support this finding,
since we also demonstrate that conditions that promote intact
mitochondria (and therefore intact mitochondrial NAD levels)
prevents neuron death, which we similarly reported in MNNG-
treated neurons [20] as well as in ischemia/reperfusion injury in
cardiac myocytes [22]. However, one major difference may lie in
the hypothesis. Yang et al demonstrated that mitochondrial NAD
levels regulate cell survival (independent of changes in cytosolic
NAD), whereas we demonstrated that cytosolic NAD depletion
preceded mitochondrial NAD depletion, and that mitochondrial
NAD depletion was mediated by opening of the mitochondrial
permeability transition pore and release of the mitochondrial
NAD pool [20,21]. Interestingly, our data shows that mitochon-
drial NAD levels increase after NMDA treatment. The reason for
this is still unclear, and remains to be further studied. One possible
explanation is that the increase in mitochondrial NAD level plays
a significant role in promoting cell viability, and this hypothesis
supports the findings by Yang et al [59]. Cellular NAD levels were
restored by addition of exogenous NAD, which prevented
excitotoxic neuronal death in spite of an enhanced generation of
PAR polymers. Our results show clear evidence that cytosolic
NAD depletion directly contribute to excitotoxic neuronal death,
and we outline our working hypothesis as a schematic diagram in
Figure 8.
Since the identification and characterization of sirtuins in
several age-related diseases including neurodegenerative diseases,
modulation of sirtuin activity as a therapeutic target for prevention
and cure of such diseases has received lots of interest. Sirt1 has
been extensively studied relative to the other Sirt isoforms.
Resveratrol is known to be an activator of Sirt1 in vitro, and the
mechanism of activation has been demonstrated [60,61]. Although
the role of sirtuins in neuronal survival has been recently
documented, the exact mechanism of neuroprotection by sirtuins
is still unclear and somewhat controversial. A recent report has
shown that Sirt1 is upregulated in mouse models for Alzheimer’s
disease and amyotrophic lateral sclerosis protecting against
neurodegeneration [35], whereas another report showed that
Sirt1 increasingly expressed in neurons by excitotoxic injury
induces NAD depletion enhancing neuronal death [9]. Further, it
was shown that Sirt1 protected neurons from low potassium-
induced apoptosis [62], while Sirt2, Sirt3 and Sirt6 induced
apoptosis and Sirt5 had protective effect depending on the
subcellular localization. In the present study, we reported that
only Sirt3 was markedly increased in neurons upon NMDA
induced excitotoxicity, whereas no changes in Sirt1 or other
mitochondrial Sirts (Sirt4 or 5) were detected with excitotoxic
injury.
The exact sequence of events involved in Sirt3 processing and
translocation to mitochondria is still unclear because of conflicting
data in the literature. For example, it was reported that Sirt3 is
Figure 7. Sirt3 acts as a prosurvival factor against excitotoxic injury. (A) Fluorescence image of mitochondrial ROS detected with CMH2xROS
in neuron cultures transfected with pIRES2-zsGreen1 (control vector) or pIRES2-zsGreen1-Sirt3 at 24 hrs after exposure to NMDA 30 mM. (B) The
expression of control vector alone and pIRES2 ZsGreen-1-Sirt3 in transfected neurons 24 hr after exposure to NMDA 30 mM. Cell death was analyzed
by counting the pyknotic bodies (shown as DAPI) in transfected neurons (mean 6 SEM; n=8; *P,0.01, difference from the culture transfected with
the control vector). (C) Cell death was analyzed by LDH release in neurons transfected with Sirt3 siRNA or negative control siRNA at 24 hrs after
exposure to NMDA 30 mM (mean 6 SEM; n=8; *P,0.01, difference from NMDA alone; **P,0.01, difference from NMDA plus Sirt3 siRNA).
doi:10.1371/journal.pone.0014731.g007
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[37,63], whereas another group reported that the long form is
processed in the mitochondria to the short form [58]. In this study,
immunofluorescence of Sirt3 detected by an antibody specific to
short Sirt3 was increased in both the nucleus and mitochondria in
NMDA-treated neurons, suggesting that the increase in Sirt3 by
excitotoxic conditions may occur both within and outside of
mitochondria. Also, what is unclear is our reported Sirt3 long form
size of 44 kD, which is different from the long form size (35 kD)
reported by others [64,65]. Wherever Sirt3 may be processed, our
finding presented here demonstrated that excitotoxicity induces
the increased expression and translocation of Sirt3 into mitochon-
dria in neurons.
Recent evidence demonstrated the crucial role of NAD as a
determining factor in cell survival under energetic stress, and the
role of Sirt3 as a metabolic sensor is gaining further interest. Sirt3
was reported either in mitochondria [66,67] or was shown to
translocate from the nucleus to mitochondria [63], and Sirt3
expression and/or processing has been shown to increase in
various tissues during stress conditions [37]. Prior studies showed
the role of Sirt3 in maintaining energy metabolism. The role of
Sirt3 in the maintenance of ATP level and in regulating
mitochondrial electron transport was shown using Sirt3 knockout
mice [38]. It was reported that constitutive expression of Sirt3
promoted the expression of mitochondrial genes, leading to
enhanced mitochondrial electron transport activity [37]. Interest-
ingly, we found that NAD depletion by NADase protein delivery
increased expression of mitochondrial Sirt3, whereas exogenous
treatment with NAD prevented the increase in Sirt3 and rescued
neurons. Our finding seems contradictory to a recent report that
showed the activation of Sirt3 by exogenously added NAD [11].
However, both studies demonstrated that exogenously added
NAD rescued cells. It is likely that cytosolic NAD depletion
induced mitochondrial Sirt3 to protect neurons from further
energetic stress. Similar to our findings, Hirschey et. al. showed
that Sirt3 expression was upregulated during fasting in liver and
brown adipose tissue and modulated mitochondrial fatty acid use
[68]. Our study suggested that Sirt3 could play a pivotal role in
protecting neurons from excitotoxicity-mediated energetic stress
by showing that Sirt3 was increased and activated in mitochon-
dria, another pool of NAD, upon cytosolic NAD level depletion.
Excitotoxicity induced by excessive calcium influx into neurons
initiates ionic imbalance, oxidative stress, and energy failure.
Exogenously added NAD inhibited ROS generation in neurons
treated with NMDA, whereas antioxidant agents such as trolox or
7-NI could not reduce NAD depletion. Once NAD turnover is
enhanced by NMDA receptor activation, it seems that the
treatment with antioxidants is not sufficient to prevent NAD
depletion. However, BAPTA-AM, a cell-permeable Ca
2+ chelator,
significantly prevented NAD depletion (data not shown), indicat-
ing that Ca
2+-dependent intracellular signal transduction pathways
may play an important role in this proposed mechanism. This data
further suggests that other events following excessive deregulated
[Ca
2+]c increase may also contribute to NAD depletion. For
example, we previously reported that NMDA receptor activation
promoted MPT induction presumably through excessive mito-
chondrial Ca
2+ uptake, and MPT induction promoted release of
mitochondrial Ca
2+ and contributed to deregulated [Ca
2+]c
increase [69]. In addition to reducing ROS generation, exogenous
addition of NAD almost completely prevented neuronal death,
suggesting the definitive role of NAD in inhibiting the above
events by excitotoxicity. Interestingly, we found that Trolox or 7-
NI reduced Sirt3 expression. Consistent with this result, we
observed that Sirt3 was increased in neurons treated with the
peroxynitrite generator. These observations suggest that in our
excitotoxicity model, NAD depletion is an upstream event of
oxidative stress, and seems to be primarily responsible for the
increased expression of Sirt3 in mitochondria.
What we posit is that the normal cell response to pathological
insults is to reverse this stress. In this model, excitotoxic injury
through opening of NMDA receptor-gated calcium channels
increases ROS formation through PARP-1 activation and NAD
depletion, which promotes an increase in mitochondrial Sirt3 to
reduce further ROS formation (such as ROS-induced ROS
formation). An increase in mitochondrial Sirt3 sufficient to counter
further ROS formation will prevent injury, and inadequate mSirt3
will promote pathological ROS formation and subsequent cellular
demise. Thus, a delicate balance exists to promote either cell
survival (increase in mSirt3) or cell death (increase in ROS),
depending on the degree of response. This is described in our
schematic diagram (Fig. 8).
The role of Sirt3 in regulating ROS production has been
demonstrated in recent studies. Constitutively expressed Sirt3 was
shown to reduce ROS in adipocytes [37], and the increased
expression of Sirt3 protected myocytes from genotoxic and
oxidative stress and blocked cardiac hypertrophy by activating
antioxidant enzymes such as MnSOD and catalase [40,46].
Recently, Sirt3 knock out mouse embryonic fibroblast was shown
Figure 8. Schematic Diagram of NMDA-induced increase in
mitochondrial Sirt3. The proposed mechanism showing the role of
Sirt3 in protecting against NMDA-induced excitotoxic injury. NMDA
binds to the NMDA receptor which opens the ion channel and allows
for calcium (Ca
2+) influx into the cell and promotes oxidative stress.
Oxidative DNA damage activates PARP-1 and decreases NAD, leading to
an increase in ROS production due to mitochondrial failure. The
increase in ROS promotes an increase in mitochondrial Sirt3.
Mitochondrial Sirt3 levels were increased in NMDA-treated neurons
following PARP-1 mediated NAD depletion. Further evidence is
provided to support this hypothesis through genetic modification:
Overexpression of Sirt3 prevented the increase in ROS production and
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findings, we found that increased expression of mitochondrial Sirt3
significantly reduced ROS production following excitotoxic injury,
whereas Sirt3 silencing increased ROS production. Neurons
transfected with Sirt3-overexpressing plasmid showed less mito-
chondrial ROS production following excitotoxic injury. Our
finding implies that the expression of Sirt3 in mitochondria was
increased in response to oxidative stress following excitotoxic
injury, which is required for neuroprotection against oxidative
stress-mediated death. Moreover, the overexpression of Sirt3
inhibited excitotoxicity-mediated neuronal death, whereas Sirt3
siRNA transfection exacerbated neuronal death. The exact
mechanism of how Sirt3 decreases mitochondrial ROS production
in neurons is unclear and remains to be further investigated. Since
the role of Sirt3 in neuronal survival has not been established, our
study provides the first evidence that Sirt3 plays a pivotal role in
neuronal survival under stress condition such as excitotoxic injury.
In conclusion, we have shown that increased Sirt3 in
mitochondria plays a pivotal role in neuroprotection against
NMDA induced excitotoxicity, and sheds light into the effects of
Sirt3 on the regulation of neuronal survival. We demonstrated that
NAD depletion and subsequent oxidative stress induced the
increase of Sirt3 in neurons under NMDA-mediated oxidative
stress. Since oxidative stress and energetic failure contribute to
neurodegeneration, the roles of Sirt3 in controlling ROS
generation and maintaining energy homeostasis have profound





(DPQ) and PJ34 were obtained from Calbiochem (Gibbstown, NJ).
MitoTracker, DAPI, dihydroethidium (HEt), CMH2xROS, and 3-
morpholinosydnonimine (SIN1) were obtained through Invitrogen
(Carlsbad, CA). All other reagents were purchased from Sigma
Chemical (St. Louis, MO) except where otherwise noted. The
studies were approved by the San Francisco Veterans Affairs
Medical Center (SFVAMC) animal studies committee.
Mice
PARP-1-deficient mice [13] were generated from targeted
129S2/SvPas-derived D3 ES cells in isogenic C57BL/6 mice
(genetic designation 129S-Parp1
tm1Zqw/J, JAX stock number
002779) using a targeting vector containing a neomycin resistance
gene to disrupt exon 2 of the parp gene. The chimeric animals
obtained were backcrossed for 8–12 generations with wild-type
(wt) littermate C57BL/6 mice to generate PARP-1 knockout
C57BL/6 mice. PARP-1 knockout mice were backcrossed for 8–
12 generations with CD-1 mice to obtain F3 CD-1/C57BL/6
mice in order to generate PARP-1 knockout PARP-1
2/2 CD-1
mice. Heterozygous (PARP1
+/2) mice were then bred to obtain
litters consisting of homozygous (PARP-1
2/2), heterozygous
(PARP-1
+/2), and wt siblings. Homozygous PARP-1
2/2 and wt
mice were identified by PCR genotyping. All animals were
maintained in specific pathogen-free conditions according to the
regulation of the SFVAMC animal studies committee. Tissues
from Sirt3 deficient mice were contributed by Dr. Gary Cecchini,
and the mice originated from Dr. Frederick Alt’s group.
Primary neuron culture
An animal protocol for ethical use of animals for research was
approved by the San Francisco Veterans Affairs Medical Center
animal studies committee (ACORP Nos. 07-040-03 and 07-010-
03). The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). Cerebral
cortical cultures were prepared as previously described [20,21,57]
from 15-day mouse embryos in MEM medium (Invitrogen)
containing 2 mM glutamine, 10% FBS, and 1% penicillin and
streptomycin. A colony of PARP-1
2/2 mice [13] and the wt
littermates were maintained on-site. On DIV (days in vitro) 2,
10 mM cytosine arabinoside was added for 24 h to prevent glial
proliferation. The neurons were subsequently maintained in
serum-free neurobasal medium (Invitrogen) containing 2% B27
supplement and 2 mM glutamine at 37uC in a humidified 5%
CO2 incubator, and were given fresh media every 3–4 days.
Experiments were conducted on DIV 9–10 by exchanging the
culture medium with Hank’s balanced salt solution (HBSS)
containing 1.2 mM CaCl2, 0.8 mM MgSO4 (Invitrogen).
NAD assay
NAD assay was performed as previously described [20,21,57].
Neurons were extracted in 0.5 N HClO4, neutralized with 3 M
KOH/125 mM Gly-Gly buffer (pH 7.4), and centrifuged at
10,0006 g for 5 min. Supernatants were mixed with a reaction
medium containing 0.1 mM 3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyl-tetrazolium bromide (MTT), 0.9 mM phenazine metho-
sulfate, 13 units/ml alcohol dehydrogenase, 100 mM nicotin-
amide, and 5.7% ethanol in 61 mM Gly-Gly buffer (pH 7.4). The
A560 nm was determined immediately and after 10 min, and results
were calibrated with NAD standards. Results were normalized to
protein content as determined by the bicinchonic acid (BCA)
method. The NMDA-induced NAD decrease was compared
among the different experiments and not found to be statistically
significant.
Neuronal death
Between days 9 and 10 in vitro (DIV 9–10), cultures were rinsed
with HBSS and treated for 24 h with 30 mM NMDA, with or
without other drugs. Cell death was quantified as previously
described [21] by measuring lactate dehydrogenase (LDH) release
into the bathing medium over 24 h and was expressed as a
percentage of cell death induced by a maximally cytotoxic
concentration (500 mM) of NMDA: (LDH2LDHcontrol)/
(LDHNMDA2LDHcontrol)6100%. Difference in NMDA-induced
neuronal death among the different experimental groups were
compared and not found to be statistically significant.
Western blot analysis
Western blots were prepared as described [21]. Neuron cultures
were lysed and collected in RIPA buffer (Cell signaling) with
1 mM PMSF on ice for 30 minutes. Cell lysates were centrifuged
at 14,000 g for 10 minutes, and cell extracts were mixed with a 1:4
volume of SDS–PAGE loading buffer (10% b-mercaptoethanol,
10% glycerol, 4% SDS, 0.01% bromophenol blue, and 62.5 mM
Tris–HCl, pH 6.8) and heated to 65uC for 15 min. Samples were
loaded on a 10% resolving SDS–polyacrylamide gel, and
transferred to polyvinyldifluoridine membranes. Membranes were
incubated overnight at 4uC with rabbit polyclonal anti-Sirt1, anti-
Sirt3, anti-Sirt5, goat polyclonal anti-Sirt5 (1:500; Abcam), rabbit
polyclonal anti-Acetyl-lysine (1:1,000; Biomol), rabbit polyclonal
anti-PAR (1:1,000; Trevigen) or rabbit polyclonal anti-b-actin
(1:5,000; Abcam) antibodies, and then reacted with anti-rabbit or
anti-goat secondary antibodies (1:10,000; Vector Laboratories).
Immunoreactivity was detected with luminol reagent (GE).
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Mitochondria were isolated as described previously [21], using
mitochondrial isolation kit (Thermo Fisher Scientific) according to
the manufacturer’s protocol. Cells were grown on 6-well plates as
described, and were harvested with a scraper in 0.5 mL of
isolation medium (320 mM sucrose, 1 mM potassium EDTA, and
10 mM Tris–HCl pH 7.4). Cells were homogenized in a glass
Teflon homogenizer, and were centrifuged at 5006g for 5 min at
4uC. The supernatant fractions (S1) were saved (at 4uC) for the
subsequent centrifugation step. The pellet was re-homogenized
and centrifuged at 5006g for 10 min at 4uC. The supernatant (S2)
was combined with S1 and centrifuged at 5006g for 10 min at
4uC. The supernatant was collected, and centrifuged at 16,0006g
for 30 min. The final pellet (mitochondrial fraction) was
resuspended in 200 ml of isolation medium and kept on ice for
biochemical studies. Mitochondrial enrichment was quantified by
western blots using an antibody targeted to the mitochondrial
protein cytochrome C oxidase IV (cox IV).
RT PCR analysis
Total RNA was isolated using Trizol reagent (Invitrogen). First
strand cDNA synthesis was performed using Superscript II reverse
transcriptase primed with oligo dT primers (Invitrogen). PCR was
performed in 50 ml volumes under the following condition; 94uC
for 2 min, followed by 30 cycles of 94uC for 30 sec, 55uC for
30 sec, and 72uC for 45 sec, and 72uC for 10 min. Sense and
antisense primers were: GCCTGCAAGGTTCCTACTCC and
TCGAGGACTCAGAACGAACG for Sirt3; TCCATGACAAC-
TTTGGCATCGTGG and GTTGCTGTTGAAGTCACAG-
GAGAC for GAPDH. PCR product was analyzed using LAS-
4000 luminescent image analyzer (Fuji).
Immunocytochemistry
Cortical neurons were fixed in 4% paraformaldehyde for
10 min and immunostained using anti-goat Sirt3 antibody (1:200
dilution; Santa Cruz) at 4uC for overnight. Immunostaining was
visualized with Alexa Fluor 488–conjugated antibody (1:400
dilution; Invitrogen). Cell fluorescence was captured using a Zeiss
LSM 510 META confocal laser scanning module mounted onto
an inverted Axio Observer (Zeiss), using a 406 EC Plan-
NEOFLUAR (NA 1.3) oil objective. Data was acquired with the
Zeiss LSM 510 AIM software. All imaging was performed at RT.
NAD glycohydrolase transfection
NAD glycohydrolase (NADase; Sigma, St. Louis, MO) protein
transfection was performed as previously described [21]. Briefly,
NADase was diluted to 1–5 mg/ml in PBS, and NADase was
diluted in HBSS to the proper working concentrations (1–500 mg/
mL) as determined after calculating the activity units, and mixed
with BioPorter reagent (Gene Therapy Systems, San Diego, CA)
and the BioPORTER-protein complex was subsequently diluted
in HBSS. The cell cultures were incubated with the BioPORTER-
protein complex for 3–4 hr at 37uC and immediately used for
experiments. Positive controls (fluorescein-labeled antibody and b-
galactosidase) were used to verify protein transfection (data not
shown).
ROS production
ROS generation was assayed with minor modifications using
chloromethyl derivative of dihydro X-rosamine (or CM-
H2XROS; Invitrogen), a modified version of MitoTracker Red,
and dihydroethidium (HEt; Invitrogen, [71]. Cultures were loaded
with 5 mM HEt or 300 nM CM-H2XROS in HBSS for 20 min at
37uC and washed 3 times with HBSS. The image of ROS was
captured at 37uC using a Zeiss LSM 510 META confocal laser
scanning module mounted onto an inverted Axio Observer (Zeiss)
(for HEt excitation=546 nm and emission=590 nm; for oxidized
CM-H2XROS, excitation=580 nm and emission=600 nm).
Constructs of Sirt3- expressing vector
Total RNA was isolated from cultured mouse primary cortical
neurons and used for RT-PCR to produce the coding region of
mouse Sirt3. First strand cDNA synthesis was performed with1 ml
of total RNA as template using Superscript II reverse transcriptase
(Invitrogen). The DNA sequences of Sirt3 primers with restriction
enzyme sites for cloning were as follows - forward primer with
EcoRI site; 59-CCGGAATTCCGGATGGTGGGGGCCGG-
CATC-39, reverse primer with XmaI site; 59-CCCCCCG-
GGGGGTTATCTGTCCTGTCCATCCAGCTT-39 (Integrat-
ed DNA technologies). The PCR was performed under the
following condition: 94uC for 2 min, followed by 40 cycles of 94uC
for 30 sec, 58uC for 30 sec, 68uC for 1 min 30 sec. The Sirt3
coding sequence produced by PCR was cut by EcoRI and XmaI,
and inserted into pIRES2-zsGreen1vector (Clontech) for con-
struction of pIRES2-zsGreen-Sirt3. pIRES2-zsGreen1 with no
insert was used as control vector. The pIRES2-zsGreen vector was
only used to label cells that transfected successfully, and not to
label Sirt3 localization.
Transfection of primary cortical neurons
For transfection of primary neurons Neon transfection kit
(Invitrogen) was used according to the manufacturer’s instructions.
Primary cortical neurons collected from 15 day CD1 mouse
embryos were prepared at final concentration of 5610
7/ml in
resuspension buffer (Invitrogen), 10 ml of which per well in 24 well
plate was transfected with 0.5 mg of vector or 100 nM of Sirt3
siRNA (Ambion) at 1500 V with two pulses of 10 ms. Transfected
neuron cultures were used on DIV 8–10.
Data Analysis
Data are presented as means 6 SEM. Statistical significance
was assessed using ANOVA and the Student-Newman-Keuls post
hoc test to compare the indicated experimental groups. The ‘‘n’’
denotes the number of independent experiments, each performed
with independently prepared cultures. Values from 2–4 culture
wells were averaged to generate each data point within each
experiment. P,0.01 were considered significant.
Supporting Information
Figure S1 Detection of Sirt3 by immunoblotting in brain tissue
from Sirt3 WT and KO mice. Sirt3 proteins at 44 kDa and
28 kDa were detected in WT but not in Sirt3 KO mice brain
tissues.
Found at: doi:10.1371/journal.pone.0014731.s001 (0.81 MB TIF)
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